Please amend claims 8 and 15 and add new claims 19 to 25 as follows before calculating the filing fee for the above-identified application:

8. (Amended) Process for the preparation of a compound of formula (I) according to [any one of] Claim[s] 1 [to 5 and 7], ~~characterized in that~~ wherein:

(1) either when Z = NR11R12, in which R11 and R12 are as defined for (1):

(1a) when at least one of the $R_{11}$ and $R_{12}$ radicals is different from hydrogen, a compound of formula:




(II A)

in which $R_1$, $R_2$, $R_3$, $R_4$, W, Cy and T are as defined for (I) and in which X is a halogen or a sulphonic acid derivative is reacted with a derivative of formula ZH in a solvent selected from dimethylformamide, tetrahydrofuran or acetonitrile, at temperatures of between 0° and 120°C;

(1b) when $R_{11}$ and $R_{12}$ = H, the compound (IIA), in which X is an azido, is reduced to amino;

(2) or, when Z = -COOH, a compound of formula:




(II' A)

in which $R_1$, $R_2$, W, $R_3$, $R_4$ and Cy are as defined for (I) and T' represents T-$CH_2$-, is oxidized in an acid solvent at a temperature of between 0°C and 100°C, alkali metal dichromates or alkali metal or alkaline-earth metal permanganates;

(3) or a compound of formula:

T820X




(II B)

in which $R_1$, $R_2$, Cy, T and Z are as defined for (I), is reacted with a compound of formula:

T821X




(2)

in which W, $R_3$ and $R_4$ are as defined for (I) and Hal represents a halogen atom, in an anhydrous solvent in the presence of a metal hydride or an alkali metal alkoxide at temperatures of between -40° and 25°C;

(4) or, when Z = -COOH, a compound of formula:

T822X




(II' B)

in which $R_1$, $R_2$ and Cy are as defined above for (I) and T' represents $T\text{-}CH_2$, is oxidized [to (I)], then the acid thus obtained of formula:

T823X




(II" B)

in which $R_1$, $R_2$, Cy and T are as defined above for (I), is subsequently optionally protected by a protective group for the carboxylic acid, in order to obtain the intermediate of formula:

T830Y




(II" BP)

in which $R_1$, $R_2$, Cy and T are as defined for (I) and P represents a protective group chosen from an alkyl, a *tert*-butyl or a benzyl, and, finally, this compound (II"BP) is subjected to the action of a derivative of formula (2) in order to obtain, after deprotection, a compound (I); one of its quaternary ammoniums, oxides, sulphones or salts.

14 ~~15.~~ **(Amended)** Pharmaceutical composition according to [any one of] Claim[s] ~~9~~ 8 [to 14] also containing another active principle.

Please add the following new claims:

--~~19~~ 18. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.--

--~~20~~ 19. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.--

--~~21~~ 20. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.--

--~~22~~ 21. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.--

--~~23~~ 22. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 5.--